Navigation Links
InCode BioPharmaceutics Appoints New President and CEO
Date:11/20/2008

SAN FRANCISCO, Nov. 20 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging company in complement depletion, announced that it has appointed Kevin L. Stark, Ph.D. as President and Chief Executive Officer, effective immediately. Dr. Stark has more than 19 years experience as a biopharmaceutical researcher and executive, most recently as an Executive Director at Amgen, and Chief Operating Officer at iZumi Bio, Inc. His latest responsibilities included strategic operations within R&D, integration of mergers and acquisitions, licensing, and business development.

"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter, Ph.D., Chairman of the Board. "We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships."

Dr. Stark received a Ph.D. in Pharmacology from the University of Washington, and a B.S. in Zoology from Colorado State University.

InCode also announced that William St. John has resigned as President and Chief Executive Officer, and will remain on the Board of Directors.

"We are very grateful to Bill for his vision in recognizing the promise of complement depletion in human disease, and his role in building the company to this point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member, from the Cancer Research Center of Hawaii.

In conjunction with this transition, the company will shift operations from the San Francisco, CA location to the Thousand Oaks, CA area.

About InCode

InCode's novel approach is focused on the selective interruption of the complement cascade. Activation of the complement cascade has been implicated in the pathogenesis of many inflammatory diseases, including rheumatoid arthritis, asthma, ischemia-reperfusion injury and age-related macular degeneration. Importantly, there is increased appreciation for the role of complement in certain types of cancer.

    For more information, contact:
    info@incodebp.com
   http://www.incodebp.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE InCode BioPharmaceutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. GeneNews appoints Canadian Colorectal Cancer Advisory Board
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
5. Accumetrics Appoints John J. Young, MD Chief Medical Officer
6. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
7. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. NutraCea Appoints New Chief Financial Officer
10. Cardiac Science Appoints Dave Marver as Chief Operating Officer
11. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... November Research ... leading biopharmaceutical and medical device manufacturers and regulators, is proud to announce the ... 11-compliant email client designed to provide product vigilance departments with the flexibility and ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading ... grant applications subject to the existing policy. AMIA recommended that NIH earmark funding ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
Breaking Biology Technology:
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... (ctDNA) technologies, today announced that it has signed agreements ... and the Middle East ... milestone marks the first wave of international distribution agreements ... and blood samples. The initial partners will ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
Breaking Biology News(10 mins):